ERBB2 and non-small cell lung carcinoma: Moreover, the efficacy of immunotherapy has not been systematically investigated in HER2 non‐ex20ins patients, owing to the low prevalence of HER2 mutations in NSCLC and the focus on HER2 ex20ins.